FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / Therapeutic management of ocular squamous cell carcinoma in ...
Equine veterinary journal1991; 23(6); 449-452; doi: 10.1111/j.2042-3306.1991.tb03759.x

Therapeutic management of ocular squamous cell carcinoma in the horse: 43 cases (1979-1989).

Abstract: The records of 50 horses with ocular squamous cell carcinoma (OSCC) presented to the University of Florida Veterinary Medical Teaching Hospital over an 11 year period were reviewed to determine the influence of therapy on the outcome of the case. Follow-up information was obtained for 43 of the 50 cases. The disease was more prevalent in the light horse breeds; however, the draft breeds also were at risk. There was no sex predisposition and the average age was 11.8 years. Tumour recurrence was significant when surgery alone was performed. The eyelid and nictitating membrane were the primary sites for tumor recurrence. Cases in which adjunctive therapy was used correlated with a lower rate of recurrence.
Get Full Text
Publication Date: 1991-11-01 PubMed ID: 1778163DOI: 10.1111/j.2042-3306.1991.tb03759.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article discusses a review of 50 cases of horses with ocular squamous cell carcinoma (OSCC), their treatment strategies, and the impact of these strategies on disease recurrence, focusing particularly on 43 cases with complete follow-up information.

Context and Objective

  • The study analyses data from the University of Florida Veterinary Medical Teaching Hospital, spanning over a period of 11 years.
  • The primary objective was to determine the influence of different therapeutic approaches on the outcome of horses diagnosed with ocular squamous cell carcinoma (OSCC), a common type of eye cancer observed in horses.

Patient Characteristics

  • The study involved 50 horses with OSCC, with follow-up information available for 43 cases.
  • While this type of cancer was more prevalent in light horse breeds, the study noted that draft breed horses were also susceptible.
  • There were no significant differences in terms of sex, and the average age among the cases was approximately 11.8 years.

Therapeutic Management and Outcomes

  • One of the key findings was that tumour recurrence was higher in cases where only surgery was used as the treatment modality.
  • Most recurrent tumours were observed in the eyelid and the nictitating membrane (an additional protective fold that animals have on the inner side of their eyes).
  • The use of adjunctive therapy, treatments applied alongside surgery, tended to result in a lower rate of tumour recurrence. This underscores the potential importance of using additional treatments alongside surgery to ensure the best possible outcome for the horse.

Implications

  • These findings suggest that effective management of ocular squamous cell carcinoma in horses might necessitate an integrated therapeutic approach involving surgery and adjunctive therapies.
  • Further studies are required to establish the most beneficial combination of treatments to lower the rate of recurrence and improve the clinical outcomes for equines affected by OSCC.

Cite This Article

APA
King TC, Priehs DR, Gum GG, Miller TR. (1991). Therapeutic management of ocular squamous cell carcinoma in the horse: 43 cases (1979-1989). Equine Vet J, 23(6), 449-452. https://doi.org/10.1111/j.2042-3306.1991.tb03759.x

Publication

Equine veterinary journal
ISSN: 0425-1644
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 23
Issue: 6
Pages: 449-452

Researcher Affiliations

King, T C
  • Department of Small Animal Clinical Sciences/Comparative Ophthalmology, College of Veterinary Medicine, University of Florida, Gainesville 32610-0126.
Priehs, D R
    Gum, G G
      Miller, T R

        MeSH Terms

        • Age Factors
        • Animals
        • Breeding
        • Carcinoma, Squamous Cell / epidemiology
        • Carcinoma, Squamous Cell / therapy
        • Carcinoma, Squamous Cell / veterinary
        • Combined Modality Therapy
        • Eye Neoplasms / epidemiology
        • Eye Neoplasms / therapy
        • Eye Neoplasms / veterinary
        • Female
        • Follow-Up Studies
        • Horse Diseases / epidemiology
        • Horse Diseases / therapy
        • Horses
        • Male
        • Neoplasm Recurrence, Local / veterinary
        • Prevalence
        • Retrospective Studies
        • Sex Factors

        Citations

        This article has been cited 10 times.
        1. Wotman KL, Chow L, Martabano B, Pezzanite LM, Dow S. Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia. Cancer Immunol Immunother 2023 May;72(5):1185-1198.
          doi: 10.1007/s00262-022-03321-2pubmed: 36367558google scholar: lookup
        2. Flores MM, Del Piero F, Habecker PL, Langohr IM. A retrospective histologic study of 140 cases of clinically significant equine ocular disorders. J Vet Diagn Invest 2020 May;32(3):382-388.
          doi: 10.1177/1040638720912698pubmed: 32207378google scholar: lookup
        3. Jeanes EC, Koll-Hampp S, Dawson C, Dunkel B, Tetas Pont R. Rhomboid blepharoplasty and cryotherapy for the treatment of a squamous cell carcinoma on the lower eyelid in a horse. Clin Case Rep 2019 Jan;7(1):40-46.
          doi: 10.1002/ccr3.1907pubmed: 30656005google scholar: lookup
        4. Scheck JL. Treatment of an ocular squamous cell carcinoma in a stallion with atrial fibrillation. Can Vet J 2005 Oct;46(10):922-4.
          pubmed: 16454385
        5. Reid SW, Mohammed HO. Longitudinal and cross-sectional studies to evaluate the risk of sarcoid associated with castration. Can J Vet Res 1997 Apr;61(2):89-93.
          pubmed: 9114958
        6. Dagenais A, Juette T, Benoit-Biancamano MO, Vanore M. Reducing Recurrence in Equine Corneolimbal SCC: Outcomes of Adjunctive Cisplatin Biodegradable Bead Therapy. Vet Sci 2026 Jan 12;13(1).
          doi: 10.3390/vetsci13010076pubmed: 41600732google scholar: lookup
        7. Quatember H, Nell B, Richter B, Rigler D, Dolezal M, Sykora S, Wallner B. Studying the Impact of the DDB2 T338M Missense Mutation on the Development of Equine Squamous Cell Carcinoma and Sarcoid. Animals (Basel) 2025 Mar 22;15(7).
          doi: 10.3390/ani15070911pubmed: 40218305google scholar: lookup
        8. Ing ST, Pinard CL, James-Jenks EM, Leis ML. A retrospective survey of equine ocular diseases evaluated at a referral hospital in Ontario (2011 to 2021). Can Vet J 2025 Mar;66(3):308-317.
          pubmed: 40070935
        9. Chow L, Flaherty E, Pezzanite L, Williams M, Dow S, Wotman K. Impact of Equine Ocular Surface Squamous Neoplasia on Interactions between Ocular Transcriptome and Microbiome. Vet Sci 2024 Apr 7;11(4).
          doi: 10.3390/vetsci11040167pubmed: 38668434google scholar: lookup
        10. Martabano BB, Dow S, Chow L, Williams MMV, Mack MK, Bellone R, Wotman KL. Intralesional interferon alpha-2b as a novel treatment for periocular squamous cell carcinoma in horses. PLoS One 2024;19(2):e0297366.
          doi: 10.1371/journal.pone.0297366pubmed: 38381740google scholar: lookup
        Subscribe to our newsletter
        Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.